Medullary thyroid cancer: New targeted molecular therapies

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 4, Issue 1, 2010, Pages 10-14

  Antonelli, Alessandro ^a   Martina Ferrari, Silvia ^a   Fallahi, Poupak ^a   Minuto, Michele ^a   Corrado, Alda ^a   Bruno, Rossella ^a   Miccoli, Paolo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Medullary thyroid cancer; Targeted molecular therapies; Tyrosine kinase inhibitors

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ANGIOGENESIS INHIBITOR; AXITINIB; DACARBAZINE; IMATINIB; MOTESANIB; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TAUTOMYCETIN; TAUTOMYCIN; TYROSINE KINASE RECEPTOR; VANDETANIB;

ABDOMINAL DISCOMFORT; ACNE; ADVANCED CANCER; BLEEDING; CLINICAL TRIAL; DIARRHEA; DRUG ERUPTION; DRUG TOLERABILITY; FATIGUE; GENE MUTATION; HUMAN; HYPERTENSION; KIDNEY TUMOR; METASTASIS; MOLECULAR THERAPY; MUCOSA INFLAMMATION; NAUSEA; PANCREAS TUMOR; PRIORITY JOURNAL; REVIEW; THYROID CANCER; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VON HIPPEL LINDAU DISEASE;

EID: 77951110391     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221410790226765     Document Type: Review

References (61)

1. Kloos RT, Eng C, Evans DB, et al. American Thyroid Association Guidelines Task Force. Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 2009; 19: 565-612.
2. Sipple JH. The association of pheochromocytoma with carcinoma of thyroid gland. Am J Med 1961; 31: 163-166.
3. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET protooncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2: 851-856.
4. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 3: 458-460.
5. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985; 42: 581-588.
6. Wohllk N, Cote GJ, Bugalho MM, et al. Relevance of RET protooncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996; 81: 3740-3745.
7. Moura MM, Cavaco BM, Pinto AE, et al. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 2009; 100: 1777-1783.
8. Pasini B, Hofstra RM, Yin L, et al. The physical map of the human RET proto-oncogene. Oncogene 1995; 119: 1737-1743.
9. Anders J, Kjar S, Ibáñez CF. Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. J Biol Chem 2001; 276: 35808-35817.
10. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006; 275: 535-560.
11. Verdy M, Weber AM, Roy CC, Morin CL, Cadotte M, Brochu P. Hirschsprung's disease in a family with multiple endocrine neoplasia type 2. J Pediatr Gastroenterol Nutr 1982; 14: 603-607.
12. Gagel RF, Levy ML, Donovan DT, Alford BR, Wheeler T, Tschen JA. Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med 1989; 111: 802-806.
13. Farndon JR, Geraghty JM, Dilley WG, Handwerger S, Leight GS. Familial medullary thyroid carcinoma without associated endocrinopathies: A distinct clinical entity. Br J Surg 1986; 73: 278-281.
14. Williams ED, Pollock DJ. Multiple mucosal neuromata with endocrine tumours: A syndrome allied to von Recklinghausen's disease. J Pathol Bacteriol 1966; 91: 71-80.
15. Lombardo F, Baudin E, Chiefari E, et al. Familial medullary thyroid carcinoma: Clinical variability and low aggressiveness associated with RET mutation at codon 804. J Clin Endocrinol Metab 2002; 87: 1674-1680.
16. Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. Oncologist 2008; 13: 539-547.
17. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: Recommendations for extent of node dissection. Ann Surg 1999; 229: 880-887.
18. Zhou GW, Wei Y, Chen X, et al. Diagnosis and surgical treatment of multiple endocrine neoplasia. Chin Med J (Engl) 2009; 122: 1495-1500.
19. Allen SM, Bodenner D, Suen JY, Richter GT. Diagnostic and surgical dilemmas in hereditary medullary thyroid carcinoma. Laryngoscope 2009; 119: 1303-1311.
20. Evans DB, Fleming JB, Lee JE, Cote G, Gagel RF. The surgical treatment of medullary thyroid carcinoma. Semin Surg Oncol 1999; 16: 50-63.
21. Machens A, Lorenz K, Dralle H. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: Value of pretherapeutic calcitonin levels. Ann Surg 2009; 250: 305-310.
22. Machens A, Dralle H. Prophylactic thyroidectomy in RET carriers at risk for hereditary medullary thyroid cancer. Thyroid 2009; 19: 551-554.
23. Riggins, G., Cerutti, J.: US20090068171A1 (2009).
24. Schwartz DL, Rana V, Shaw S, et al. Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern era. Head Neck 2008; 30: 883-1838
25. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: Analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996; 6: 305-310.
26. Strasser JF, Raben A, Koprowski C. The role of radiation therapy in the management of thyroid cancer. Surg Oncol Clin N Am 2008; 17: 219-232.
27. Díez JJ, Iglesias P. Somatostatin analogs in the treatment of medullary thyroid carcinoma. J Endocrinol Invest 2002; 25: 773-778.
28. Monsieurs M, Brans B, Bacher K, Dierckx R, Thierens H. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans. Eur J Nucl Med Mol Imaging 2002; 29: 1581-1587.
29. Zatelli, M. C., Culler, M. D., Delgi Uberti, E. C.: US20090099094A1 (2009).
30. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25: 458-511.
31. Choquet-Kastylevsky, G., Demont, Y., Hondermarck, H.: US20090068200 (2009).
32. Adler JT, Cook M, Luo Y, et al. Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta. Mol Cancer Ther 2009; 8: 914-920.
33. Drosten M, Pützer BM. Mechanisms of Disease: Cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat Clin Pract Oncol 2006; 3: 564-574.
34. Sebolt-Leopold JS, English JM. Mechanisms of drug inhibition of signalling molecules. Nature 2006; 441: 457-462.
35. Santoro M, Carlomagno F. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract Endocrinol Metab 2006; 2: 42-52.
36. Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474): An orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 2007; 16: 239-249.
37. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62: 7284-7290.
38. Dinsmore, C. J., Beshore, D. C., Bergman, J.M., Lindsley, C. W.: US20090186871 (2009).
39. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-844.
40. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006; 98: 326-934.
41. Chow LQ, Eckhardt SG. Sunitinib: From rational design to clinical efficacy. J Clin Oncol 2007; 25: 884-896.
42. Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006; 66: 8715-8721.
43. Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 2009; 94: 1493-1499.
44. Malouf G, Baudin E, Soria JC, Schlumberger M. Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies. Bull Cancer 2009; 96: 95-101.
45. Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an openlabel phase II trial 43rd ASCO Congress, Chicago, IL USA (2007).
46. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 3466-3469.
47. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 2008; 26: 4708-4713.
48. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008; 359: 31-42.
49. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009; 27: 3794-3801.
50. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26: 4714-4719.
51. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27: 1675-1684.
52. Jimenez C, Cabanillas ME, Santarpia L, et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: Targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 2009; 94: 386-391.
53. Hong D, Ye L, Gagel R, et al. Medullary thyroid cancer: Targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 2008; 7: 1001-1006.
54. Kelleher FC, McDermott R. Response to sunitinib in medullary thyroid cancer. Ann Intern Med 2008; 148: 567.
55. Fassnacht M, Kreissl MC, Weismann D, Allolio B. New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 2009; 123: 117-141.
56. Schroyens W, Tueni E, Dodion P, Bodecker R, Stoessel F, Klastersky J. Validation of clinical predictive value of in vitro colorimetric chemosensitivity assay in head and neck cancer. Eur J Cancer 1990; 26: 834-838.
57. Antonelli A, Fallahi P, Ferrari SM, et al. Dedifferentiated thyroid cancer: A therapeutic challenge. Biomed Pharmacother 2008; 62: 559-563.
58. Antonelli A, Ferrari SM, Fallahi P, et al. Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur J Endocrinol 2008; 159: 283-291.
59. Antonelli A, Ferrari SM, Fallahi P, et al. Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Clin Endocrinol (Oxf) 2008; 69: 148-152.
60. van Veelen W, de Groot JW, Acton DS, et al. Medullary thyroid carcinoma and biomarkers: Past, present and future. J Intern Med 2009; 266: 126-140.
61. Santarpia L, Ye L, Gagel RF. Beyond RET: Potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. J Intern Med 2009; 266: 99-113.